Vaxcyte, Inc. Common Stock
PCVX
$48.44
-7.54%
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on engineering high-fidelity vaccines to protect against bacterial diseases using its proprietary XpressCF cell-free protein synthesis platform. The company is a disruptive player in the vaccine space, developing novel conjugate and protein vaccine candidates for adult and pediatric indications, including its lead programs VAX-24 and VAX-31 targeting pneumococcal disease. The current investor narrative is overwhelmingly centered on the late-stage clinical progress and blockbuster commercial potential of its lead pneumococcal conjugate vaccine (PCV) candidates, which are designed to offer broader serotype coverage and potentially superior efficacy compared to established market leaders, driving significant anticipation ahead of key regulatory milestones and commercial launch.…
PCVX
Vaxcyte, Inc. Common Stock
$48.44
PCVX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vaxcyte, Inc. Common Stock's 12-month outlook, with a consensus price target around $62.97 and implied upside of +30.0% versus the current price.
Average Target
$62.97
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$39 - $63
Analyst target range
Insufficient analyst coverage data is available in the provided dataset to determine a consensus price target, Buy/Hold/Sell distribution, or a specific target range. The data shows only 6 analysts providing estimates, but no explicit price targets or recommendations are listed. This level of coverage is typical for a clinical-stage biotech and indicates the stock is still followed by a specialized subset of healthcare investors. The lack of broad, established consensus targets can lead to higher volatility and less efficient price discovery, as the stock is more susceptible to binary news flow from clinical trials and regulatory events rather than quarterly earnings revisions. The institutional ratings data provided shows a series of 'Buy' reiterations from firms like BTIG, Guggenheim, and Needham throughout 2025 and early 2026, indicating sustained bullish sentiment among the covering analysts, likely based on anticipation for the company's pivotal clinical data readouts and regulatory filings.
Bulls vs Bears: PCVX Investment Factors
The bull case for PCVX, driven by explosive technical momentum, a clean balance sheet, and blockbuster revenue potential, is currently stronger based on market price action and analyst sentiment. However, this strength is built on highly speculative future events. The single most important tension in the investment debate is between the stock's current premium valuation—which prices in near-certain clinical success and commercial dominance—and the stark reality of its pre-revenue status, massive cash burn, and binary regulatory risk. The resolution of this tension through upcoming clinical and regulatory catalysts will definitively determine the stock's trajectory.
Bullish
- Powerful Technical Uptrend: The stock has delivered a 103.4% return over the past year and is trading at 96% of its 52-week high of $65, demonstrating sustained momentum and strong investor conviction in the clinical narrative. This price action reflects a high degree of market anticipation for upcoming regulatory milestones.
- Strong Balance Sheet & Low Debt: Vaxcyte maintains a fortress balance sheet with a current ratio of 7.91 and a minimal debt-to-equity ratio of 0.085. This provides significant financial runway to fund its late-stage clinical programs without the immediate pressure of dilutive capital raises.
- Blockbuster Commercial Potential: Analyst consensus points to forward revenue estimates of $2.56 billion, reflecting the multi-billion dollar market opportunity for its lead pneumococcal vaccine candidates. The company's $6.28 billion market cap is a direct bet on capturing a significant share of this market.
- Sustained Analyst Bullishness: Institutional analysts from firms like BTIG and Needham have consistently reiterated 'Buy' ratings throughout 2025 and 2026. This sustained positive sentiment among the limited covering analysts underscores confidence in the clinical and commercial thesis.
Bearish
- Pre-Revenue with High Cash Burn: The company reported $0 in revenue for Q4 2025 and a net loss of -$246.5 million, with an operating cash burn of -$224.8 million for the quarter. This unsustainable burn rate necessitates future capital raises, risking shareholder dilution before any product sales materialize.
- Valuation Priced for Perfection: With a market cap of $6.28B against zero current revenue, the stock's valuation is entirely speculative and contingent on flawless clinical and regulatory execution. The forward P/E of -8.55 indicates the market is paying for deeply negative earnings, leaving no margin for error.
- Extreme Volatility & High Beta: The stock's beta of 1.386 indicates it is 39% more volatile than the broader market, which is typical for clinical-stage biotechs but poses significant risk. This is compounded by a high short interest ratio of 10.38, suggesting a sizable bearish contingent betting against success.
- Binary Clinical & Regulatory Risk: As a single-asset story centered on its pneumococcal vaccines, the investment thesis is exposed to binary outcomes from pivotal trial data and FDA reviews. A clinical setback or regulatory delay could trigger a severe drawdown, as evidenced by the stock's historical max drawdown of -63.2%.
PCVX Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +103.43% and a 6-month gain of +47.09%. As of the latest close at $62.35, the stock is trading at approximately 96% of its 52-week high of $65.0, indicating it is near peak momentum levels which suggests both strong investor conviction and potential for near-term consolidation or profit-taking. Recent short-term momentum remains robust but shows signs of deceleration; the stock is up 14.87% over the past month and 33.83% over three months, though the 1-month gain is notably lower than the 3-month performance, hinting at a possible moderation in the explosive rally. The stock exhibits high volatility with a beta of 1.386, meaning it is approximately 39% more volatile than the broader market, which is typical for a clinical-stage biotech and necessitates careful risk management. Key technical levels are clear, with immediate resistance at the 52-week high of $65.0 and support near the 52-week low of $28.09; a decisive breakout above $65 could signal a new leg higher, while a breakdown below the recent consolidation range around $54-$60 would suggest a deeper correction.
Beta
1.30
1.30x market volatility
Max Drawdown
-23.2%
Largest decline past year
52-Week Range
$29-$65
Price range past year
Annual Return
+52.1%
Cumulative gain past year
| Period | PCVX Return | S&P 500 |
|---|---|---|
| 1m | -22.3% | +4.0% |
| 3m | -9.2% | +8.2% |
| 6m | -0.4% | +11.5% |
| 1y | +52.1% | +24.3% |
| ytd | +4.3% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PCVX Fundamental Analysis
As a pre-revenue clinical-stage company, Vaxcyte's fundamental story is defined by investment in R&D and a path to future commercialization. The company reported $0 in revenue for the most recent quarter (Q4 2025), consistent with prior periods, as it has not yet launched a product. The net loss for Q4 2025 was -$246.51 million, with an EPS of -$1.81, reflecting the substantial costs of advancing its pipeline through late-stage clinical trials. Profitability metrics are not applicable, with gross margin, operating margin, and net margin all at 0%, but the critical focus is on the burn rate and cash position to fund operations to commercialization. The balance sheet remains strong with a healthy current ratio of 7.91 and a very low debt-to-equity ratio of 0.085, indicating minimal financial leverage. However, cash flow is deeply negative, with operating cash flow of -$224.83 million and free cash flow of -$219.26 million for Q4 2025, underscoring the company's dependence on its cash reserves and future capital raises to fund its ambitious clinical programs until it can generate product sales.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-669290000.0B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PCVX Overvalued?
Given the company's negative net income, the primary valuation metric is the Price-to-Sales (PS) ratio; however, with zero current revenue, the trailing PS ratio is 0, making forward-looking sales estimates critical. The forward-looking sales estimate for the company is $2.56 billion, which the market is beginning to price in ahead of potential product launches. Peer comparison using traditional multiples is challenging due to the lack of revenue, but the stock's $6.28 billion market cap reflects a high-conviction bet on the future commercial success of its pipeline, particularly in the multi-billion-dollar pneumococcal vaccine market. Historically, the stock's valuation has expanded significantly as it has advanced its lead candidates; for instance, its Price-to-Book (PB) ratio has risen from 3.04 at the end of 2024 to 2.34 as of Q4 2025, though this decrease is partly due to equity raises increasing the book value. The current valuation sits near the upper end of its historical range on most metrics, pricing in a high probability of clinical and regulatory success, leaving little margin for error.
PE
-8.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -34x~-6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's complete lack of revenue and accelerating cash burn. With $0 in sales, a Q4 2025 net loss of -$246.5 million, and quarterly operating cash flow of -$224.8 million, Vaxcyte is entirely dependent on its cash reserves and future capital markets access to fund operations. The company's R&D expenses surged to $242.1 million in Q4 2025 from $133.6 million a year prior, indicating a rapid ramp in clinical trial costs that will continue to pressure the balance sheet. Any delay in its path to commercialization would necessitate significant equity dilution at potentially unfavorable prices.
Market & Competitive Risks are elevated due to the stock's speculative valuation and competitive landscape. Trading at a $6.28 billion market cap with no revenue, the stock is vulnerable to severe multiple compression if clinical timelines slip or investor sentiment towards pre-profit biotech sours. The company is aiming to disrupt the established pneumococcal vaccine market dominated by large pharmaceutical companies with deep commercial resources. Furthermore, the stock's high beta of 1.386 makes it highly sensitive to broader market downturns, which could trigger outflows from speculative growth assets irrespective of company-specific progress.
Worst-Case Scenario involves a material clinical setback for lead candidate VAX-24 or VAX-31, such as failing to meet primary efficacy endpoints in a pivotal trial. This would likely collapse the commercial thesis, trigger analyst downgrades, and lead to a rapid re-rating of the stock towards its net asset value. A realistic downside could see the stock retracing to its 52-week low of $28.09, representing a potential loss of approximately -55% from the current price of $62.35. This scenario is quantified by the stock's historical maximum drawdown of -63.2%, demonstrating its capacity for severe declines on negative news.
